NYSE:MNK - Mallinckrodt Stock Price, Price Target & More

Get Started

$16.11 +0.22 (+1.38 %)

(As of 05/23/2018 06:42 AM ET)

Previous Close$15.89

Today's Range$15.70 - $16.43

52-Week Range$11.65 - $49.12

Volume1.94 million shs

Average Volume3.77 million shs

Market Capitalization$1.32 billion

P/E Ratio2.15

Dividend YieldN/A

Beta1.13

About Mallinckrodt (NYSE:MNK)

Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers H.P. Acthar Gel, an injectable drug for various indications, such as proteinuria, multiple sclerosis, infantile spasms, ophthalmic, neuromuscular disorders, dermatomyositis, polymyositis, rheumatology, and pulmonology; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; Therakos, an immunotherapy treatment platform; and Amitiza for the treatment of chronic idiopathic constipation. The company is also developing StrataGraft, which is in Phase III and II clinical development for the treatment of burns; terlipressin for the treatment of hepatorenal syndrome; MNK-1411 for the treatment of Duchenne muscular dystrophy; Stannsoporfin, a heme oxygenase inhibitor for the treatment of jaundice; Xenon gas for inhalation; MNK-6105, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; VTS-270 that is in Phase III development for Niemann-Pick Type C, a neurodegenerative fatal disease; and CPP-1X/sulindac, which is in Phase III development for Familial Adenomatous Polyposis. Mallinckrodt public limited company markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. The company is based in Staines-Upon-Thames, the United Kingdom.

Receive MNK News and Ratings via Email

Sign-up to receive the latest news and ratings for MNK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNYSE:MNK

CUSIPN/A

Webwww.mallinckrodt.com

Phone44-0-17-8463-6700

Debt

Debt-to-Equity Ratio1.00

Current Ratio2.10

Quick Ratio1.90

Price-To-Earnings

Trailing P/E Ratio2.15

Forward P/E Ratio2.58

P/E Growth0.26

Sales & Book Value

Annual Sales$3.22 billion

Price / Sales0.42

Cash Flow$16.4388 per share

Price / Cash0.98

Book Value$77.77 per share

Price / Book0.21

Profitability

EPS (Most Recent Fiscal Year)$7.49

Net Income$2.13 billion

Net Margins57.56%

Return on Equity11.59%

Return on Assets4.48%

Miscellaneous

Employees3,900

Outstanding Shares83,080,000

Mallinckrodt (NYSE:MNK) Frequently Asked Questions

What is Mallinckrodt's stock symbol?

Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."

How will Mallinckrodt's stock buyback program work?

Mallinckrodt declared that its board has authorized a stock repurchase program on Sunday, April 9th 2017, which permits the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to purchase up to 18.5% of its stock through open market purchases. Stock buyback programs are often a sign that the company's board of directors believes its shares are undervalued.

How were Mallinckrodt's earnings last quarter?

Mallinckrodt PLC (NYSE:MNK) announced its quarterly earnings data on Tuesday, May, 8th. The company reported $1.31 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.08 by $0.23. The firm earned $572.60 million during the quarter, compared to analyst estimates of $568.78 million. Mallinckrodt had a net margin of 57.56% and a return on equity of 11.59%. The business's revenue for the quarter was up 2.2% compared to the same quarter last year. During the same period in the prior year, the company posted $1.04 EPS. View Mallinckrodt's Earnings History.

When is Mallinckrodt's next earnings date?

Mallinckrodt is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Mallinckrodt.

What guidance has Mallinckrodt issued on next quarter's earnings?

Mallinckrodt issued an update on its FY earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of $6.00-6.50 for the period, compared to the Thomson Reuters consensus estimate of $7.14. The company issued revenue guidance of +3-6% to ~$.

What price target have analysts set for MNK?

19 analysts have issued 12-month price objectives for Mallinckrodt's shares. Their forecasts range from $12.00 to $67.00. On average, they expect Mallinckrodt's stock price to reach $31.2632 in the next twelve months. View Analyst Ratings for Mallinckrodt.

What are Wall Street analysts saying about Mallinckrodt stock?

Here are some recent quotes from research analysts about Mallinckrodt stock:

1. Cantor Fitzgerald analysts commented, "Positives from the quarter that support our thesis: 1) YTD (today), total debt has decreased by roughly ~$215MM. the end of 1Q18 was 4.6x, an expected increase from last quarter, following the close of the SCMP deal., 2) MNK presented its free cash flow guidance for the first time. This is expected to be ~$0.5B in 2018. Operating cash flow in 1Q18 of ~$18MM was impacted primarily by assumed liabilities paid following the close of the SCMP transaction. MNK expects free cash flow to return to more normal levels the remainder of the year., 3) While debt reduction is MNK’s top priority with respect to capital allocation for 2018, MNK did repurchase 2.9MM shares in 1Q18." (5/8/2018)
2. Mizuho analysts commented, "We plan to remove all risk-adjusted estimates for this compound from our model after the earnings call, which will be somewhat offset by the greater than $0.15-$0.20 in dilution to adjusted earnings expected in 2018″." (5/3/2018)
3. According to Zacks Investment Research, "Mallinckrodt is selling its hemostasis products for Baxter. The company aims to focus better on its specialty pharmaceutical business after having sold its Nuclear Imaging business.Mallinckrodt is facing challenging conditions as lead drug Acthar sales declined on volume while weaknesses in the generics segment persist. Acthar declined as specialty drugs face payer environment and the decline is expected to continue in the fourth quarter as well. The company's generic segment continues to face weakness as various product categories are witnessing stiff competition, which is hurting both their volumes and prices. Shares of the company have underperformed the industry in the last six months. A U.S. District Court recently invalidated 11 patents covering its second-largest product Inomax. As a result, Mallinckrodt is looking to diversify its portfolio with the recently announced Sucampo acquisition and counter the decline in existing drugs." (1/9/2018)

Who are some of Mallinckrodt's key competitors?

Some companies that are related to Mallinckrodt include GALAPAGOS NV/S (GLPG), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Hutchison China MediTech (HCM), FibroGen (FGEN), GW Pharmaceuticals (GWPH), Ligand Pharmaceuticals (LGND), Blueprint Medicines (BPMC), Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD) and Supernus Pharmaceuticals (SUPN).

Who are Mallinckrodt's key executives?

Mallinckrodt's management team includes the folowing people:

Mr. Mark Christopher Trudeau, Pres, CEO & Director (Age 57)
Mr. Matthew K. Harbaugh, Exec. VP & CFO (Age 48)
Dr. Frank Scholz, Exec. VP of Global Operations & Pres of Specialty Generics (Age 49)
Mr. Hugh M. O'Neill, Exec. VP and Pres of Autoimmune & Rare Diseases (Age 55)
Dr. Gary M. Phillips, Exec. VP & Chief Strategy Officer (Age 52)

Has Mallinckrodt been receiving favorable news coverage?

Media coverage about MNK stock has been trending somewhat positive on Wednesday, according to Accern. Accern identifies negative and positive press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Mallinckrodt earned a media sentiment score of 0.11 on Accern's scale. They also assigned media headlines about the company an impact score of 45.92 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Mallinckrodt's major shareholders?

Mallinckrodt's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Scopia Capital Management LP (10.38%), BlackRock Inc. (9.38%), Dimensional Fund Advisors LP (4.91%), LSV Asset Management (3.04%), Robeco Institutional Asset Management B.V. (1.66%) and Millennium Management LLC (1.30%). Company insiders that own Mallinckrodt stock include Coleman N Lannum III, David R Carlucci, Dr Kneeland Youngblood, Hugh M O'neill, James E Flynn, Joann A Reed, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks and Steven J Romano. View Institutional Ownership Trends for Mallinckrodt.

Which major investors are selling Mallinckrodt stock?

MNK stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Schroder Investment Management Group, Prudential Financial Inc., Legal & General Group Plc, State of Wisconsin Investment Board, Allianz Asset Management GmbH, A.R.T. Advisors LLC and BNP Paribas Arbitrage SA. View Insider Buying and Selling for Mallinckrodt.

Which major investors are buying Mallinckrodt stock?

MNK stock was acquired by a variety of institutional investors in the last quarter, including Scopia Capital Management LP, Millennium Management LLC, Robeco Institutional Asset Management B.V., Dimensional Fund Advisors LP, Neuberger Berman Group LLC, UBS Group AG, Engineers Gate Manager LP and Seven Eight Capital LP. Company insiders that have bought Mallinckrodt stock in the last two years include Coleman N Lannum III, David R Carlucci, Dr Kneeland Youngblood, Hugh M O'neill, Joann A Reed, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks and Steven J Romano. View Insider Buying and Selling for Mallinckrodt.

How do I buy shares of Mallinckrodt?

Shares of MNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mallinckrodt's stock price today?

One share of MNK stock can currently be purchased for approximately $16.11.

How big of a company is Mallinckrodt?

Mallinckrodt has a market capitalization of $1.32 billion and generates $3.22 billion in revenue each year. The company earns $2.13 billion in net income (profit) each year or $7.49 on an earnings per share basis. Mallinckrodt employs 3,900 workers across the globe.

How can I contact Mallinckrodt?

Mallinckrodt's mailing address is 3 LOTUS PARK THE CAUSEWAY STAINES-UPON-THAMES, SURREY X0, TW18 3AG. The company can be reached via phone at 44-0-17-8463-6700 or via email at [email protected]

MarketBeat Community Rating for Mallinckrodt (MNK)

Community Ranking:		3.1 out of 5 ( )
Outperform Votes:		629 (Vote Outperform)
Underperform Votes:		381 (Vote Underperform)
Total Votes:		1,010

MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt and other stocks. Vote "Outperform" if you believe MNK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Mallinckrodt (NYSE:MNK) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

19 Wall Street analysts have issued ratings and price targets for Mallinckrodt in the last 12 months. Their average twelve-month price target is $31.2632, suggesting that the stock has a possible upside of 94.06%. The high price target for MNK is $67.00 and the low price target for MNK is $12.00. There are currently 1 sell rating, 13 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.21	2.22	2.33	2.42
Ratings Breakdown:	1 Sell Rating(s) 13 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 12 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 10 Hold Rating(s) 7 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 11 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$31.2632	$33.8333	$42.6389	$47.9737
Price Target Upside:	94.06% upside	157.68% upside	134.93% upside	129.76% upside

Mallinckrodt (NYSE:MNK) Consensus Price Target History

Price Target History for Mallinckrodt (NYSE:MNK)

Mallinckrodt (NYSE:MNK) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/15/2018	Oppenheimer	Reiterated Rating	Hold		Low
5/9/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$27.00 ➝ $14.00	High
5/9/2018	Barclays	Set Price Target	Underweight ➝ Underweight	$20.00 ➝ $12.00	High
5/8/2018	Canaccord Genuity	Set Price Target	Hold	$14.00	High
5/8/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$42.00	Medium
5/4/2018	Wells Fargo & Co	Set Price Target	Hold	$17.50 ➝ $15.00	Low
5/3/2018	Mizuho	Reiterated Rating	Hold	$15.00	Medium
5/2/2018	B. Riley	Initiated Coverage	Neutral ➝ Neutral	$15.00 ➝ $15.00	Low
4/23/2018	Leerink Swann	Lower Price Target	Market Perform		Low
4/12/2018	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$50.00	High
4/11/2018	SunTrust Banks	Initiated Coverage	Hold	$15.00	High
1/1/2018	Goldman Sachs	Reiterated Rating	Hold		High
11/26/2017	UBS	Downgrade	Buy ➝ Neutral	$70.00 ➝ $24.00	Medium
11/8/2017	BMO Capital Markets	Lower Price Target	Outperform	$38.00	N/A
11/8/2017	Jefferies Group	Initiated Coverage	Market Perform ➝ Buy	$60.00 ➝ $30.00	N/A
11/7/2017	Citigroup	Downgrade	Buy ➝ Hold	$44.00 ➝ $28.00	N/A
11/7/2017	Deutsche Bank	Downgrade	Buy ➝ Hold	$44.00 ➝ $28.00	N/A
10/21/2017	Piper Jaffray Companies	Set Price Target	Buy	$67.00	N/A
8/9/2017	Raymond James	Lower Price Target	Outperform	$65.00 ➝ $58.00	Low
4/1/2017	Guggenheim	Set Price Target	Buy	$98.00	Low
1/25/2017	JPMorgan Chase	Set Price Target	Hold	$78.00	N/A

(Data available from 5/23/2016 forward)

Mallinckrodt (NYSE:MNK) Earnings History and Estimates Chart

Earnings by Quarter for Mallinckrodt (NYSE:MNK)

Mallinckrodt (NYSE:MNK) Earnings Estimates

2018 EPS Consensus Estimate: $6.09
2019 EPS Consensus Estimate: $5.24

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	5	$1.08	$1.55	$1.21
Q2 2018	6	$1.37	$1.65	$1.52
Q3 2018	6	$1.57	$1.75	$1.66
Q4 2018	6	$1.50	$1.85	$1.71
Q1 2019	1	$1.10	$1.10	$1.10
Q2 2019	1	$1.41	$1.41	$1.41
Q3 2019	1	$1.41	$1.41	$1.41
Q4 2019	1	$1.32	$1.32	$1.32

Mallinckrodt (NYSE MNK) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/14/2018
5/8/2018	Q1 2018	$1.08	$1.31	$568.78 million	$572.60 million	View	N/A
2/27/2018	Q4 2017	$1.72	$2.01	$769.91 million	$792.30 million	View	Listen
11/7/2017	Q3 2017	$1.80	$1.97	$808.93 million	$793.90 million	View	N/A
8/8/2017	Q2 2017	$1.73	$1.85	$829.56 million	$824.50 million	View	Listen
5/8/2017	Q1 2017	$1.63	$1.68	$781.23 million	$810.90 million	View	Listen
2/7/2017	Q117	$1.82	$1.91	$827.12 million	$829.90 million	View	Listen
11/29/2016	Q416	$1.98	$2.04	$880.10 million	$887.20 million	View	Listen
8/2/2016	Q316	$2.01	$2.20	$920.35 million	$970.60 million	View	Listen
5/3/2016	Q216	$1.72	$2.01	$878.70 million	$918.00 million	View	Listen
2/2/2016	Q116	$1.78	$2.09	$888.33 million	$915.00 million	View	Listen
11/23/2015	Q415	$1.77	$1.84	$869.41 million	$882.40 million	View	Listen
8/4/2015	Q315	$1.82	$2.05	$983.81 million	$965.10 million	View	Listen
5/5/2015	Q215	$1.48	$1.72	$860.89 million	$909.90 million	View	Listen
2/3/2015	Q115	$1.57	$1.84	$880.12 million	$866.00 million	View	Listen
11/19/2014	Q414	$1.41	$1.68	$759.04 million	$789.00 million	View	Listen
8/7/2014	Q314	$0.86	$1.20	$278.80 million	$653.10 million	View	Listen
5/8/2014	Q214	$0.79	$0.95	$566.50 million	$557.80 million	View	Listen
2/6/2014	Q1	$0.66	$0.88	$539.24 million	$540.20 million	View	Listen
11/7/2013		$0.85	$1.02	$572.57 million	$552.20 million	View	Listen
8/9/2013	Q3 2013	$0.78	$0.49	$557.22 million	$570.00 million	View	Listen

(Earnings results data provided by Zacks Investment Research)

Mallinckrodt (NYSE:MNK) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Mallinckrodt (NYSE MNK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.80%

Insider Trading History for Mallinckrodt (NYSE:MNK)

Institutional Ownership by Quarter for Mallinckrodt (NYSE:MNK)

Mallinckrodt (NYSE MNK) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/16/2018	Mark Trudeau	Insider	Buy	3,000	$15.54	$46,620.00
5/9/2018	James E Flynn	Insider	Sell	312,928	$13.39	$4,190,105.92
11/28/2017	Dr Kneeland Youngblood	Director	Buy	4,560	$21.94	$100,046.40	19,789
11/13/2017	Joann A Reed	Director	Buy	1,000	$21.50	$21,500.00	15,554
11/13/2017	Steven J. Romano	VP	Buy	2,000	$21.96	$43,920.00
11/10/2017	Mark Trudeau	CEO	Buy	5,000	$22.28	$111,400.00
11/9/2017	David R Carlucci	Director	Buy	10,000	$21.83	$218,300.00	26,020
11/9/2017	Michael-Bryant Hicks	General Counsel	Buy	7,900	$20.80	$164,320.00
8/30/2017	Meredith B. Fischer	Insider	Buy	1,280	$39.63	$50,726.40
6/9/2017	Steven J. Romano	VP	Buy	1,000	$39.88	$39,880.00
6/8/2017	Hugh M. O'neill	VP	Buy	1,000	$40.24	$40,240.00
6/5/2017	Coleman N Lannum III	VP	Buy	500	$39.33	$19,665.00	31,455
6/2/2017	Coleman N Lannum III	VP	Buy	1,350	$42.89	$57,901.50	30,955
5/12/2017	Coleman N. Lannum III	VP	Buy	1,968	$46.20	$90,921.60
3/10/2017	Matthew K. Harbaugh	CFO	Buy	600	$49.19	$29,514.00
3/7/2017	Michael-Bryant Hicks	General Counsel	Buy	290	$50.35	$14,601.50
2/23/2017	Meredith B. Fischer	Insider	Buy	2,000	$54.34	$108,680.00
2/14/2017	Mark Trudeau	Insider	Buy	1,000	$50.47	$50,470.00
2/10/2017	Steven J. Romano	VP	Buy	1,000	$49.68	$49,680.00
5/10/2016	Hugh M O'neill	VP	Buy	1,653	$60.99	$100,816.47	15,623
5/10/2016	Matthew K Harbaugh	CFO	Buy	500	$59.37	$29,685.00	56,036
5/6/2016	Mark Trudeau	CEO	Buy	1,000	$56.02	$56,020.00	192,546
5/6/2016	Steven J Romano	VP	Buy	900	$56.00	$50,400.00	9,291
3/4/2016	Coleman N Lannum III	VP	Buy	2,600	$62.63	$162,838.00	20,556
2/26/2016	Meredith B Fischer	VP	Buy	1,400	$69.80	$97,720.00	17,643
2/12/2016	Coleman N Lannum III	VP	Buy	600	$59.66	$35,796.00	17,940
2/10/2016	Coleman N Lannum III	VP	Buy	1,300	$62.58	$81,354.00	17,340
2/9/2016	Matthew K. Harbaugh	CFO	Buy	1,300	$63.00	$81,900.00
2/8/2016	Coleman N. Lannum III	VP	Buy	800	$66.37	$53,096.00
12/22/2015	Coleman N Lannum III	SVP	Buy	500	$72.50	$36,250.00	11,266
12/11/2015	Terrance L Carlson	General Counsel	Buy	1,000	$69.10	$69,100.00	2,549
12/2/2015	Gary M. Phillips	VP	Buy	1,000	$72.17	$72,170.00	7,728
11/30/2015	Mark Trudeau	CEO	Buy	1,350	$65.89	$88,951.50	167,526
11/27/2015	Coleman N Lannum III	SVP	Buy	1,200	$66.86	$80,232.00	9,986
11/27/2015	Meredith B Fischer	VP	Buy	2,200	$66.93	$147,246.00	14,280
11/27/2015	Terrance L Carlson	General Counsel	Buy	1,000	$66.54	$66,540.00	1,453
8/25/2015	Hugh M O'neill	SVP	Buy	1,197	$83.52	$99,973.44	9,015
8/25/2015	Mark Trudeau	CEO	Buy	1,000	$83.08	$83,080.00	166,176
8/21/2015	Coleman N Lannum III	SVP	Buy	2,375	$88.52	$210,235.00	7,361
8/21/2015	Mark Trudeau	CEO	Buy	2,000	$88.45	$176,900.00	165,176
6/4/2015	Coleman N Lannum III	VP	Buy	1,300	$126.41	$164,333.00
6/2/2015	Matthew K Harbaugh	CFO	Sell	22,106	$128.64	$2,843,715.84
5/18/2015	Mario D Saltarelli	VP	Sell	4,580	$127.44	$583,675.20
5/13/2015	Don M Bailey	Director	Sell	51,417	$122.45	$6,296,011.65
5/11/2015	Sandra L Hatten	VP	Sell	2,024	$122.29	$247,514.96
4/13/2015	Don M Bailey	Director	Sell	40,000	$127.61	$5,104,400.00
3/13/2015	Don M Bailey	Director	Sell	40,000	$123.40	$4,936,000.00
2/13/2015	Don M Bailey	Director	Sell	33,891	$114.63	$3,884,925.33
2/2/2015	Mark Trudeau	CEO	Sell	11,925	$105.94	$1,263,334.50
1/9/2015	Mark Trudeau	CEO	Sell	15,720	$102.00	$1,603,440.00
12/22/2014	Peter G Edwards	VP	Sell	1,265	$99.69	$126,107.85
12/18/2014	Mark Trudeau	CEO	Sell	13,831	$93.59	$1,294,443.29
9/10/2014	Raymond J Furey	VP	Sell	5,441	$85.90	$467,381.90
9/8/2014	Don M Bailey	Director	Sell	221,177	$85.23	$18,850,915.71
9/5/2014	Raymond J Furey	VP	Sell	15,000	$85.47	$1,282,050.00
9/5/2014	Virgil D Thompson	Director	Sell	25,000	$83.76	$2,094,000.00
9/2/2014	Raymond J Furey	VP	Sell	10,303	$81.61	$840,827.83
8/29/2014	Raymond J Furey	VP	Sell	4,840	$80.90	$391,556.00
8/19/2014	Joseph A Zaccagnino	Director	Buy	3,000	$71.06	$213,180.00
8/13/2014	Paulson & Co Inc	Major Shareholder	Buy	132,100	$69.80	$9,220,580.00
8/12/2014	J Martin Carroll	Director	Buy	2,000	$69.24	$138,480.00
8/12/2014	Paulson & Co Inc	Major Shareholder	Buy	467,900	$68.78	$32,182,162.00
8/11/2014	Paulson & Co Inc	Major Shareholder	Buy	207,900	$69.70	$14,490,630.00
8/7/2014	Paulson & Co Inc	Major Shareholder	Buy	700,200	$70.15	$49,119,030.00
8/1/2014	Paulson & Co Inc	Major Shareholder	Buy	275,000	$69.60	$19,140,000.00
6/11/2014	Melvin D Booth	Director	Buy	4,000	$76.05	$304,200.00
5/9/2014	Paulson & Co Inc	major shareholder	Buy	786,207	$73.63	$57,888,421.41
2/3/2014	Mark Trudeau	CEO	Sell	14,890	$56.12	$835,626.80

(Data available from 1/1/2013 forward)

Mallinckrodt (NYSE MNK) News Headlines

Source:

Date	Headline
	Mallinckrodt (MNK) Insider Mark Trudeau Purchases 3,000 Shares www.americanbankingnews.com - May 18 at 8:35 PM
	Appeals court nixes Mallinckrodt patent on respiratory treatment www.reuters.com - May 18 at 9:07 AM
	Q2 2018 EPS Estimates for Mallinckrodt Lifted by B. Riley (MNK) www.americanbankingnews.com - May 18 at 7:16 AM
	Mallinckrodt Forecasted to Earn Q2 2018 Earnings of $1.37 Per Share (MNK) www.americanbankingnews.com - May 18 at 7:13 AM
	Mallinckrodt (MNK) Expected to Announce Quarterly Sales of $621.54 Million www.americanbankingnews.com - May 18 at 2:02 AM
	Mallinckrodt: Appeals Court Rules Inomax Patent Invalid seekingalpha.com - May 17 at 5:53 PM
	BioDelivery Sciences Announces Agreement with Broadfin Capital on Comprehensive Plan to Strengthen Business finance.yahoo.com - May 17 at 8:47 AM
	Zacks: Analysts Anticipate Mallinckrodt (MNK) to Post $1.54 Earnings Per Share www.americanbankingnews.com - May 16 at 7:10 PM
	Mallinckrodt's (MNK) "Hold" Rating Reiterated at Oppenheimer www.americanbankingnews.com - May 16 at 3:40 PM
	Mallinckrodt: Acthar Continues To Crack seekingalpha.com - May 15 at 5:33 PM
	Mallinckrodt To Present At Goldman Sachs 39th Annual Global Healthcare Conference finance.yahoo.com - May 14 at 5:07 PM
	Q4 2018 EPS Estimates for Mallinckrodt Cut by SunTrust Banks (MNK) www.americanbankingnews.com - May 14 at 4:03 AM
	Mallinckrodt Forecasted to Earn Q2 2018 Earnings of $1.48 Per Share (MNK) www.americanbankingnews.com - May 14 at 2:15 AM
	Leerink Swann Comments on Mallinckrodt's Q4 2018 Earnings (MNK) www.americanbankingnews.com - May 11 at 11:03 AM
	Research Analysts Issue Forecasts for Mallinckrodt's Q1 2019 Earnings (MNK) www.americanbankingnews.com - May 11 at 11:02 AM
	Q3 2018 Earnings Forecast for Mallinckrodt (MNK) Issued By SunTrust Banks www.americanbankingnews.com - May 11 at 10:15 AM
	James E. Flynn Sells 312,928 Shares of Mallinckrodt (MNK) Stock www.americanbankingnews.com - May 10 at 7:22 PM
	Hospital Product Sales Drive Mallinckrodt (MNK) Q1 Earnings finance.yahoo.com - May 10 at 5:34 PM
	Here's Why Mallinckrodt PLC Rose as Much as 16.3% Today www.fool.com - May 10 at 8:47 AM
	Equities Analysts Set Expectations for Mallinckrodt's Q2 2018 Earnings (MNK) www.americanbankingnews.com - May 10 at 7:04 AM
	Q2 2018 EPS Estimates for Mallinckrodt (MNK) Cut by Analyst www.americanbankingnews.com - May 10 at 6:45 AM
	Mallinckrodt (MNK) to Post Q2 2018 Earnings of $1.51 Per Share, SunTrust Banks Forecasts www.americanbankingnews.com - May 10 at 6:36 AM
	Cantor Fitzgerald Remains Bullish on Mallinckrodt (MNK) Following 1Q www.streetinsider.com - May 9 at 5:16 PM
	Mallinckrodt: Why I'm No Longer Long seekingalpha.com - May 9 at 5:16 PM
	Here's Why Mallinckrodt PLC Rose as Much as 16.3% Today finance.yahoo.com - May 9 at 5:16 PM
	Mallinckrodt (MNK) Price Target Lowered to $14.00 at Morgan Stanley www.americanbankingnews.com - May 9 at 4:53 PM
	Mallinckrodt (MNK) Price Target Increased to $12.00 by Analysts at Barclays www.americanbankingnews.com - May 9 at 1:29 PM
	Mallinckrodt (MNK) PT Set at $14.00 by Canaccord Genuity www.americanbankingnews.com - May 9 at 12:08 PM
	Mallinckrodt plc (MNK) PT Lowered to $29 at BMO Capital www.streetinsider.com - May 9 at 8:42 AM
	Mallinckrodt Plc (MNK) Q1 2018 Results - Earnings Call Transcript seekingalpha.com - May 9 at 8:42 AM
	Edited Transcript of MNK earnings conference call or presentation 8-May-18 12:30pm GMT finance.yahoo.com - May 9 at 8:42 AM
	Q3 2018 EPS Estimates for Mallinckrodt (MNK) Raised by Analyst www.americanbankingnews.com - May 9 at 7:56 AM
	Form 8-K Mallinckrodt plc For: May 08 www.streetinsider.com - May 8 at 5:17 PM
	Cantor Fitzgerald Reiterates "$42.00" Price Target for Mallinckrodt (MNK) www.americanbankingnews.com - May 8 at 3:28 PM
	Mallinckrodt (MNK) Issues Quarterly Earnings Results www.americanbankingnews.com - May 8 at 11:52 AM
	Earnings Reaction History: Mallinckrodt plc, 70.0% Follow-Through Indicator, 10.1% Sensitive www.nasdaq.com - May 8 at 8:36 AM
	Mallinckrodt (MNK) Tops Q1 EPS by 22c, Beats on Revenues www.streetinsider.com - May 8 at 8:36 AM
	BRIEF-Mallinckrodt Reports Q1 Adjusted Earnings Per Share Of $1.31 www.reuters.com - May 8 at 8:36 AM
	Mallinckrodt plc Reports First Quarter 2018 Results finance.yahoo.com - May 8 at 8:36 AM
	Mallinckrodt: 1Q Earnings Snapshot finance.yahoo.com - May 8 at 8:36 AM
	Mallinckrodt Provides Facts on HP Acthar® Gel www.prnewswire.com - May 7 at 8:37 AM
	Mallinckrodt Provides Facts on H.P. Acthar® Gel finance.yahoo.com - May 7 at 8:37 AM
	SunTrust Banks Equities Analysts Boost Earnings Estimates for Mallinckrodt (MNK) www.americanbankingnews.com - May 7 at 1:56 AM
	3 Things In Biotech, May 5: Mallinckrodt Snubbed, Regenxbio Races, Portola Surprises seekingalpha.com - May 6 at 8:43 AM
	'60 Minutes' report to focus on price of Mallinckrodt drug www.cnbc.com - May 5 at 8:47 AM
	Mallinckrodt's (MNK) Market Perform Rating Reaffirmed at Wells Fargo www.americanbankingnews.com - May 4 at 7:03 PM
	Mallinckrodt (MNK) Seen as Target of Negative Upcoming 60 Minutes Episode www.streetinsider.com - May 4 at 5:12 PM
	Benzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down www.benzinga.com - May 4 at 8:35 AM
	FDA Finds Mallinckrodt's Supplemental NDA For Amitiza Lacking seekingalpha.com - May 4 at 8:35 AM
	BRIEF-Mallinckrodt Reports On FDA Joint Advisory Committee Meeting For Stannsoporfin www.reuters.com - May 4 at 8:35 AM

Mallinckrodt (NYSE:MNK) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Mallinckrodt (NYSE:MNK) Income Statement, Balance Sheet and Cash Flow Statement

Mallinckrodt (NYSE MNK) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff